(MT Newswires) -- Sanofi (SNY) Chief Financial Officer Jean-Baptiste de Chatillion discusses fourth-quarter results as the drugmaker forecasts a slowdown in profit growth with generic competition ratcheting up for multiple sclerosis drug Aubagio. He speaks with Francine Lacqua on "Bloomberg Surveillance Early Edition."
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
89.99 EUR | -0.77% | +1.61% | +0.27% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.27% | 123B | |
+42.69% | 749B | |
+39.05% | 605B | |
-6.87% | 351B | |
+18.74% | 328B | |
+6.76% | 292B | |
+11.38% | 216B | |
-2.49% | 214B | |
+2.64% | 167B | |
+6.72% | 165B |
- Stock Market
- Equities
- SAN Stock
- News Sanofi
- Sanofi Sees Trend for Years of Steady Growth: CFO